NEWS 102 FEED & ADDITIVE MAGAZINE September 2023 Hill's Pet Nutrition, a global leader in science-led nutrition, will host its annual Hill's Global Symposium, one of the largest, free global education events available for veterinary professionals. Titled "Feeding the Fight Against Cancer," this year's Hill's Global Symposium will bring together the world's leading experts in canine and feline cancer and nutrition. The event will be hosted in Lisbon, Portugal from September 25-26, 2023 and offered online, both live and on-demand, for free via Hill's global education platform, Hill's Veterinary Academy. "For the past 75 years, supporting the veterinary profession has been a top priority for Hill's Pet Nutrition. The Hill's Global Symposium allows us to support the veterinary community and build practical knowledge related to one of the leading causes of mortality in pets," said Dr. Jolle Kirpensteijn, Global Chief Veterinary Officer for Hill's Pet Nutrition and specialist in veterinary surgical oncology. "We are grateful to each of the speakers for dedicating their time and expertise as we tackle some of the most pressing topics related to oncology in cats and dogs." More than 15 sessions spanning topics such as: early detection and diagnosis, supportive care for the cancer patient and how to build a partnership with pet parents to deliver the best outcomes will be offered from renowned industry experts such as Sue Ettinger, DVM, DACVIM (Oncology), Susan Little, DVM, DABVP (Feline) and Walter L. Brown, Jr., RVTg, VTS (ECC). The full panel of speakers can be found on Hill's Veterinary Academy. "The veterinary industry is continuously evolving. Hill's Pet Nutrition helps veterinary professionals stay up to date on the latest data, trends, and treatments so they can be at their best," said Chief Veterinary Officer, Dr. Karen Shenoy of Hill's Pet Nutrition US. Read more>> Hill's Global Symposium returns with focus on veterinary oncology Mileutis, an Israeli-based biopharmaceutical company that is leading the dairy industry and animal health into a sustainable future, completed a rigorous, randomized, case-controlled, multi-center, clinical field trial. The trial was conducted at seven different commercial dairy farms and involved over 500 dairy cows. The results of this trial provide further conclusive evidence of the ability of Imilac™, therapy to completely substitute the routine use of antibiotics at dry-off in the dairy industry. In addition, the study revealed that Imilac™ is further impacting milk nutritional characteristics – a breakthrough that was patented by Mileutis. The trial was carried out in dairy farms providing milk to Israel's two largest dairy product providers – Yotvata Dairy, part of the Strauss Health Group, partially owned by Danone, and Tnuva, Israel’s largest dairy company. Antibiotics have traditionally been used to treat and manage udder inflammation in dairy cows (mastitis), the primary issue faced by the dairy industry at the beginning of the dry-off period. However, this approach, applied for too long, presents farming challenges and human health risks related to antimicrobial resistance (AMR). Mileutis has deNew trial: Mileutis reduces antibiotic use in dairy cows
RkJQdWJsaXNoZXIy MTUxNjkxNQ==